Research - OWN PCYC as Imbruvica continues to secure foothold in oncology. Cash and emerging pipeline offer options diversification for this small company. Second quarter results demonstrate continued growth … Continue Reading
PremiumResearch - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium- Alpha BioPharma Advisers, in partnership with PropThink, have undertaken a meticulous evaluation of Gilead Sciences (GILD), tackling the ongoing debate surrounding Sovaldi and Gilead’s longterm … Continue Reading
Read nowInsights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read nowInsights - Ohr Pharmaceutical (OHRP) on Tuesday released interim results from a phase 2 study of its Squalamine eye drops in Wet Age-related Macular Degeneration (AMD). Squalamine eye drops, … Continue Reading
Read nowResearch - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read nowResearch - Sarepta (SRPT) will file a NDA and get 5 new trials off the ground in the next 7 months.
Read now
